Rankings
▼
Calendar
ARQT (Arcutis Biotherapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena
ARQT
Arcutis Biotherapeutics, Inc.
Mkt Cap
$3B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$376M
Net Income (TTM)
-$16M
EPS (TTM)
-$0.14
Free Cash Flow (TTM)
-$6M
Gross Margin
90.2%
Op. Margin
-3.3%
Net Margin
-4.3%
FCF Margin
-1.7%
P/S Ratio (TTM)
8.2x
P/E Ratio (TTM)
—
YoY Rev Growth
+91.3%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$3M
$2M
-$76M
Q2 23
$5M
$4M
-$67M
Q3 23
$38M
$37M
-$37M
Q4 23
$14M
$11M
-$61M
Q1 24
$50M
$46M
-$32M
Q2 24
$31M
$27M
-$50M
Q3 24
$45M
$39M
-$39M
Q4 24
$71M
$64M
-$8M
Q1 25
$66M
$57M
-$25M
Q2 25
$82M
$74M
-$15M
Q3 25
$99M
$91M
$9M
Q4 25
$130M
$118M
$18M
marketcaparena.com
Revenue Breakdown
ARQT
Arcutis Biotherapeutics, Inc.
Revenue Breakdown
Q4 2025
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
479.0x
—
Q2 23
265.7x
—
Q3 23
63.2x
—
Q4 23
52.0x
—
Q1 24
29.1x
—
Q2 24
23.5x
—
Q3 24
22.3x
—
Q4 24
15.8x
—
Q1 25
14.6x
—
Q2 25
11.8x
—
Q3 25
9.7x
—
Q4 25
8.2x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$80M
-$80M
Q2 23
-$66M
-$67M
Q3 23
-$44M
-$44M
Q4 23
-$56M
-$56M
Q1 24
-$32M
-$32M
Q2 24
-$45M
-$45M
Q3 24
-$35M
-$35M
Q4 24
-$748K
-$6M
Q1 25
-$30M
-$31M
Q2 25
$324K
$246K
Q3 25
-$2M
-$2M
Q4 25
$26M
$26M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$82K
Q2 23
$276K
Q3 23
$64K
Q4 23
$6K
Q1 24
$0
Q2 24
$0
Q3 24
$143K
Q4 24
$5M
Q1 25
$608K
Q2 25
$78K
Q3 25
$0
Q4 25
$0
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
—
+26.2%
Q2 23
—
+9.3%
Q3 23
+5156.4%
-28.9%
Q4 23
+356.8%
+4.6%
Q1 24
+1682.4%
+2.7%
Q2 24
+494.6%
+12.5%
Q3 24
+17.4%
+11.7%
Q4 24
+427.6%
+5.8%
Q1 25
+32.8%
+11.3%
Q2 25
+164.1%
+18.8%
Q3 25
+121.7%
+8.2%
Q4 25
+81.5%
+40.7%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$9M
340.8%
Q2 23
$11M
203.8%
Q3 23
$10M
26.2%
Q4 23
$9M
64.7%
Q1 24
$10M
20.2%
Q2 24
$13M
40.6%
Q3 24
$10M
21.9%
Q4 24
$9M
13.2%
Q1 25
$10M
14.8%
Q2 25
$10M
12.9%
Q3 25
$10M
10.1%
Q4 25
$10M
7.8%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
SG&A
Quarter
R&D
G&A
S&M
SG&A
Q1 23
$35M
$6M
$37M
—
Q2 23
$25M
$46M
—
—
Q3 23
$26M
$48M
—
—
Q4 23
$24M
—
—
$49M
Q1 24
$23M
—
—
$55M
Q2 24
$19M
—
—
$58M
Q3 24
$20M
—
—
$59M
Q4 24
$14M
—
—
$58M
Q1 25
$18M
—
—
$64M
Q2 25
$19M
—
—
$69M
Q3 25
$20M
—
—
$62M
Q4 25
$20M
—
—
$79M
marketcaparena.com
Revenue Segments
Other Revenue
Product
Quarter
Other Revenue
Product
Q3 23
$30M
$8M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$81M
$251M
$332M
Q2 23
$105M
$164M
$269M
Q3 23
$107M
$120M
$227M
Q4 23
$88M
$183M
$272M
Q1 24
$191M
$214M
$404M
Q2 24
$85M
$278M
$363M
Q3 24
$135M
$196M
$331M
Q4 24
$71M
$157M
$228M
Q1 25
$53M
$145M
$198M
Q2 25
$73M
$118M
$191M
Q3 25
$47M
$144M
$191M
Q4 25
$43M
$178M
$221M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
61M
+0.3%
Q2 23
61M
+0.4%
Q3 23
62M
+0.5%
Q4 23
93M
+50.0%
Q1 24
111M
+19.9%
Q2 24
123M
+11.2%
Q3 24
124M
+0.7%
Q4 24
121M
-2.7%
Q1 25
126M
+4.2%
Q2 25
127M
+0.8%
Q3 25
133M
+4.6%
Q4 25
136M
+2.1%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 17
—
—
FY 18
—
—
FY 19
$0
29
FY 20
$0
54
FY 21
$0
147
FY 22
$14K
268
FY 23
$201K
296
FY 24
$575K
342
FY 25
$1M
354
marketcaparena.com